ArticleMedicine2020
Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea: A network meta-analysis.
Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Dysmenorrhea and psychological distress: a meta-analysis.Archives of women's mental health · 2023Pooled it
- Cai's gynecology cyclical therapy with stasis-clearing and meridian-warming method for primary dysmenorrhea: a randomized controlled trial.Frontiers in endocrinology · 2026Trial
- Single-Blind Randomized Controlled Trial: Comparative Efficacy of Dark Chocolate, Coconut Water, and Ibuprofen in Managing Primary Dysmenorrhea.International journal of environmental research and public health · 2023Trial
- Real-life use of non-pharmacological strategies and their relationship with symptom burden in primary dysmenorrhea: a cross-sectional study.BMC complementary medicine and therapies · 2026Article
- Use of over-the-counter analgesics in Norwegian children - a national cross-sectional study.Scandinavian journal of public health · 2026Article
- Reproductive Health in Young and Adolescent Females with Inflammatory Bowel Disease.Current gastroenterology reports · 2026Review
- Long-Term Management and Prevention Strategies for Adolescent Primary Dysmenorrhea: From Precision Diagnosis to Comprehensive Intervention.International journal of women's health · 2026Review
- Article
- Efficacy and Safety of Non-Pharmacological Therapies for Primary Dysmenorrhea: A Network Meta-Analysis.Journal of pain research · 2025Review
- Risk factors for severe dysmenorrhea in Arab women: A focus on war displacement and mental health outcomes.AIMS public health · 2024Article
- What a pain in the … back: a review of current treatment options with a focus on naproxen sodium.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- Assessment of the Readiness, Beliefs, and Practices Regarding Menstruation Among Women in Saudi Arabia.International journal of women's health · 2024Article
- To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics.Frontiers in endocrinology · 2024Article
- Dysmenorrhea, a Narrative Review of Therapeutic Options.Journal of pain research · 2024Review
- Three-tiered authentication of herbal traditional Chinese medicine ingredients used in women's health provides progressive qualitative and quantitative insight.Frontiers in pharmacology · 2024Article
- Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.Clinical pharmacology and therapeutics · 2023Article
- Review
- Primary Dysmenorrhea: Pathophysiology, Diagnosis, and Treatment Updates.Korean journal of family medicine · 2022Article
- A Bibliometric Analysis of Acupuncture Therapy in the Treatment of Primary Dysmenorrhea from 2001 to 2021.Journal of pain research · 2022Review
- Analysis of Healthcare Utilization for Primary Dysmenorrhea in Korea: A Retrospective, Cross-Sectional Study.International journal of women's health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary dysmenorrhea is common and troublesome. The comparative efficacy of over-the-counter analgesics (OTCAs) for dysmenorrhea is unclear. This study was aimed at conducting a network meta-analysis to assess the efficacy and safety of 5 OTCAs - naproxen, ibuprofen,diclofenac, aspirin, and ketoprofen - in patients with primary dysmenorrhea.
methodsThe study was registered with PROSPERO (number: CRD42019133556). The search strategy involved a review of PubMed, Embase, Cochrane Library, Web of Science, and CINAHL for relative randomized controlled trials of the 5 analgesics from the date of database establishment to July 2019. The outputs are presented as odds ratios (ORs), their corresponding 95% confidence intervals (CIs), and the surface under the cumulative ranking area (SUCRA) probabilities.
resultsThirty-five trials with 4383 participants were included in our study. As for efficacy outcomes, all the included analgesics except aspirin were more effective than placebo in treating dysmenorrhea [naproxen (OR 3.99, 95% CI 2.18-7.30), ibuprofen (OR 10.08, 95% CI 3.29-30.85), diclofenac (OR 11.82, 95% CI 2.66-52.48), and ketoprofen (OR 5.12, 95% CI 1.57-16.69). The OTCAs were superior to the placebo in terms of pain relief in primary dysmenorrhea. Aspirin was less effective than ibuprofen (OR 0.17, 95% CI 0.04-0.73) and diclofenac (OR 1.17, 95% CI 0.02-0.85). The SUCRA curves showed that diclofenac and ibuprofen were the most and second most effective (85.1% and 83.8%, respectively), followed by ketoprofen, naproxen, and aspirin. Regarding safety, there was no significant difference between the 5 OTCAs included and the placebo. Diclofenac versus ibuprofen (OR 4.31, 95% CI 1.18-15.67), ketoprofen versus diclofenac (OR 0.18, 95% CI 0.04-0.78), and ketoprofen versus aspirin (OR 0.41, 95% CI 0.18-0.97) presented statistically significant differences. Ketoprofen and ibuprofen were ranked the best (SUCRA 90.6% and 79.6%), followed by naproxen, aspirin, and diclofenac.
conclusionConsidering the efficacy and safety, ibuprofen is recommended as the optimal OTCA for primary dysmenorrhea. Further well-designed studies that directly compare these analgesics are needed to support our conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.